Composition comprises (a) at least one first compound comprising celecoxib etoricoxib lumiracoxib parecoxib rofecoxib valdecoxib valicoxib and (b) at least one second compound comprising: e.g. indoprofen ibuproxam ketoprofen ketorolac loxoprofen naproxen naproxen sodium oxaprozin pirprofen suprofen tiaprofenic acid and alminoprofen; salicylamide and salicyl salicylate; aceclofenac acemetacin and alclofenac; mefenamic acid flufenamic acid and meclofenamic acid; ampyrone azapropazone and clofezone...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments the ibuprofen is in direct physical contact with the famotidine.

Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments the ibuprofen is in direct physical contact with the famotidine.

A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.

The present invention discloses a stable pharmaceutical composition in a single unit dosage form comprising: a core comprising ibuprofen or salt thereof an optional barrier layer and a surrounding portion comprising famotidine or salt thereof.

Pharmaceutical compositions of a H2 receptor antagonist and ibuprofen are provided herein. The compositions comprise e.g. a core and a shell separated by a barrier layer bilayered or trilayered compositions or liquid formulations. Also provided are methods of making the pharmaceutical compositions and methods of treatment comprising administering the pharmaceutical compositions. Also provided is a method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided in w...

Pharmaceutical compositions of a H2 receptor antagonist and ibuprofen are provided herein. The compositions comprise e.g. a core and a shell separated by a barrier layer bilayered or trilayered compositions or liquid formulations. Also provided are methods of making the pharmaceutical compositions and methods of treatment comprising administering the pharmaceutical compositions. Also provided is a method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided in w...

The present invention relates to the unit dosage forms comprising a. thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as a muscle relaxant b. etodolac or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as an NSAID and c. famotidine or a pharmaceutically acceptable salt thereof as a gastroprotectant.